Showing results (371-380 of 383) with videos related to
Sort By:
Pageof 39
Bioorganic & Medicinal Chemistry Letters|September 5, 2007
Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: improving oral biovailabilityYunsong Tong, Magdalena Przytulinska, Zhi-Fu Tao, et al.Emergency and Critical Care Medicine|July 31, 2023
Clinical features of 162 fatal cases of COVID-19: a multi-center retrospective studyXianlong Zhou, Guoyong Ding, Qing Fang, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 18, 2024
The Absence of Intra-Tumoral Tertiary Lymphoid Structures is Associated with a Worse Prognosis and mTOR Signaling Activation in Hepatocellular Carcinoma with Liver Transplantation: A Multicenter Retrospective StudyJianhua Li, Li Zhang, Hao Xing, et al.Bioorganic & Medicinal Chemistry Letters|May 11, 2007
1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studiesYunsong Tong, Akiyo Claiborne, Magdalena Pyzytulinska, et al.Journal of Medicinal Chemistry|July 31, 2007
Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitorsLe Wang, Gerard M Sullivan, Laura A Hexamer, et al.Cell Biology and Toxicology|July 1, 2026
HP1γ promotes the progression of colorectal cancer through interaction with RBPJ of the Notch signaling pathwayRui-Bao Zhu, Yi-Jia Xie, Yu-Ting Han, et al.Journal of Medicinal Chemistry|February 14, 2015
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivityMilan Bruncko, Le Wang, George S Sheppard, et al.ACS Medicinal Chemistry Letters|June 20, 2014
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XLMichael F T Koehler, Philippe Bergeron, Edna F Choo, et al.Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.Molecular Cancer Therapeutics|March 31, 2021
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy VolunteersAhmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, et al.Pageof 39